Last reviewed · How we verify

Group 2 in Part B and Part C — Competitive Intelligence Brief

Group 2 in Part B and Part C (group-2-in-part-b-and-part-c) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dose 3 KAN-101 Intravenous (IV) infusion. Area: Infectious Disease.

discontinued Dose 3 KAN-101 Intravenous (IV) infusion Infectious Disease Live · refreshed every 30 min

Target snapshot

Group 2 in Part B and Part C (group-2-in-part-b-and-part-c) — Pfizer Inc.. Dose 3 KAN-101 Intravenous (IV) infusion

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Group 2 in Part B and Part C TARGET group-2-in-part-b-and-part-c Pfizer Inc. discontinued Dose 3 KAN-101 Intravenous (IV) infusion

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dose 3 KAN-101 Intravenous (IV) infusion class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Group 2 in Part B and Part C — Competitive Intelligence Brief. https://druglandscape.com/ci/group-2-in-part-b-and-part-c. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: